Haemonetics Corporation (HAE)
Automate Your Wheel Strategy on HAE
With Tiblio's Option Bot, you can configure your own wheel strategy including HAE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HAE
- Rev/Share 28.1731
- Book/Share 19.4788
- PB 3.1465
- Debt/Equity 1.3437
- CurrentRatio 1.748
- ROIC 0.0867
- MktCap 2868964613.0
- FreeCF/Share 6.5839
- PFCF 9.3126
- PE 16.3472
- Debt/Assets 0.4917
- DivYield 0
- ROE 0.2026
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HAE | Needham | Buy | Hold | -- | -- | Dec. 15, 2025 |
| Downgrade | HAE | Citigroup | Buy | Neutral | -- | $88 | Dec. 11, 2025 |
| Downgrade | HAE | Raymond James | Strong Buy | Outperform | -- | $78 | Aug. 11, 2025 |
| Downgrade | HAE | JP Morgan | Overweight | Neutral | -- | $62 | Aug. 8, 2025 |
| Reiterated | HAE | Barrington Research | -- | Outperform | $95 | $86 | Aug. 8, 2025 |
| Upgrade | HAE | Citigroup | Neutral | Buy | -- | $90 | July 9, 2025 |
| Initiation | HAE | Robert W. Baird | -- | Outperform | -- | $87 | June 26, 2025 |
| Downgrade | HAE | BofA Securities | Neutral | Underperform | $95 | $68 | Feb. 7, 2025 |
| Initiation | HAE | JP Morgan | -- | Overweight | -- | $116 | Dec. 6, 2024 |
| Initiation | HAE | CL King | -- | Buy | -- | $116 | Sept. 13, 2024 |
News
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
Published: February 20, 2026 by: PRNewsWire
Sentiment: Neutral
BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.summitcast.com/view/VSr8zRPFYu9jT7Rm69ptdC/DrZt2UmuNYtnB5faJBzE4N.
Read More
The London Company Small Cap Q4 2025 Performance And Trades
Published: February 17, 2026 by: Seeking Alpha
Sentiment: Positive
The London Company Small Cap portfolio increased 2.7% (2.5% net) during the quarter vs. a 2.2% increase in the Russell 2000 Index. Contributors to relative performance were White Mountains Insurance Group Ltd, Revolve Group Inc. and Haemonetics Corporation. Detractors from relative performance were NewMarket Corporation, Certara, Inc. and Gates Industrial Corporation plc.
Read More
Haemonetics (HAE) International Revenue Performance Explored
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Neutral
HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.
Read More
Haemonetics (HAE) Reports Q3 Earnings: What Key Metrics Have to Say
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Allspring Common Stock Fund Q4 2025 Performance Review
Published: January 28, 2026 by: Seeking Alpha
Sentiment: Neutral
In the fourth quarter, Revolve's stock rose as its revenue met expectations with a 4.4% year-over-year increase. In fiscal second quarter 2026, Haemonetics delivered strong performance, raising guidance and posting margin gains that signal operational discipline. CHWY shares declined in September after the company reported elevated selling, general, and administrative expenses.
Read More
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Haemonetics' plasma and hemostasis franchises show solid growth potential, but macro headwinds and competition cloud the near-term outlook.
Read More
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Here's Why Haemonetics (HAE) is a Strong Growth Stock
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Earn Twice The Yield You Get From Bank On HAE Stock
Published: December 30, 2025 by: Forbes
Sentiment: Positive
Currently priced at approximately $80.53 per share, Haemonetics (NYSE: HAE) is trading roughly 7.6% below its 52-week high.
Read More
Here's Why Haemonetics (HAE) is a Strong Growth Stock
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why Haemonetics (HAE) is a Strong Momentum Stock
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Top 2 Health Care Stocks You May Want To Dump This Month
Published: December 02, 2025 by: Benzinga
Sentiment: Negative
As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Read More
Touchstone Small Company Fund Q3 2025 Performance Review
Published: November 27, 2025 by: Seeking Alpha
Sentiment: Negative
The Touchstone Small Company Fund underperformed its benchmark, the Russell 2000 Index, for the quarter ended September 30, 2025. Among the Fund's top-performing sectors in terms of adding value were Financials and Consumer Staples. From a factor perspective, the Fund's focus on profitable, liquid, and higher quality small cap stocks negatively impacted relative performance during the quarter.
Read More
Touchstone Small Cap Fund Q3 2025 Contributors And Detractors
Published: November 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Among the largest contributors to Fund performance were Armstrong World Industries, Ingevity Corporation, and Graham Holdings Co. Graham Holdings outperformed the benchmark on strong second quarter results, led by solid growth in Kaplan Education and the continued expansion of its Healthcare segment. Among the largest detractors from Fund performance were Interparfums, Haemonetics Corporation, and White Mountains Insurance Group.
Read More
Interpreting Haemonetics (HAE) International Revenue Trends
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Review Haemonetics' (HAE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Read More
Here's Why Haemonetics (HAE) is a Strong Growth Stock
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Haemonetics Is Still Undervalued, Even After The Rally
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Positive
Haemonetics Corporation remains a Buy, supported by robust profit margins, strong cash flow, and leading TEG and plasma businesses driving organic growth. HAE reported improved gross and operating margins, raised full-year EPS guidance to $4.80–$5.00, and increased free cash flow outlook to $170–210 million. The company's valuation is attractive at a 14x forward P/E, below industry averages and historical norms, with potential for multiple expansion as performance stabilizes.
Read More
Haemonetics (HAE) Reports Q2 Earnings: What Key Metrics Have to Say
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
Haemonetics Corporation remains a high-quality blood-management franchise with strong TEG and plasma software moats, but recent growth has paused due to portfolio shifts and competition. Q1 FY2026 results beat expectations on margins and cash flow, but headline revenue declined due to deliberate exits and one-time factors boosting growth. HAE valuation is compelling at ~11x forward EPS and ~8x EV/EBITDA, with strong FCF and margin expansion offering attractive upside if execution improves.
Read More
Understanding Haemonetics (HAE) Reliance on International Revenue
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
Published: August 08, 2025 by: Benzinga
Sentiment: Negative
Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday.
Read More
About Haemonetics Corporation (HAE)
- IPO Date 1991-05-10
- Website https://www.haemonetics.com
- Industry Medical - Instruments & Supplies
- CEO Christopher A. Simon
- Employees 3657